Candy Smellie

ngs human genome reference standards dna sgrna crispr personalizing medicine cancer personalised medicines raav multiplex sanger sequencing single-nucleotide variants next-generation sequencing ihc ffpe clinical laboratory molecular diagnostics genome genome editing tools drug discovery target validation crispr-cas9 cancer therapies gene editing translating genomes raav and zfns diagnostics hek293 adenoviral grna oligo cas9 zinc fingers genesis™ genomic theranostics her2 biomarkers quantitative standards eqa wrt gene restriction digest analysis shrna knock out screening sirnas rnai cancer cell lines drug target suitability gene crispr─cas9 essentiality nist genome in a bottle exome bioinformatics combination drugs synergies chts antagonism mdm2 inhibitor combination immuno-oncology xenografts tumor microenvironment fish western blot molecular assays cell lines quantitative digital pathology assay controls standardization assay failure immunohistochemistry cfdna nsclc cancer biopsies dna extraction clone therapeutic strategies patients drugs genetics egfr formalin-fixed paraffin-embedded (ffpe) tissues pcr tumour optimisation validate software tumor formalin mutation synthetic lethality knock-out cell line gene targeting techniques crispr/cas9 rna talens guiderna knockout (gecko) screening sirna x-man™ isogenic cell lines rna-based screening quality management system iso 9001 fda strategy iso 13485 references standards next generation sequencing gene-editing genetic alterations dna assays guidebook™